Jon Knight - Kamada Vice Operations
| KMDA Stock | USD 5.89 0.08 1.38% |
Executive
Jon Knight is Vice Operations of Kamada
| Age | 58 |
| Address | 2 Holzman Street, Rehovot, Israel, 7670402 |
| Phone | 972 8 940 6472 |
| Web | https://www.kamada.com |
Kamada Management Efficiency
The company has return on total asset (ROA) of 0.0316 % which means that it generated a profit of $0.0316 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0705 %, meaning that it created $0.0705 on every $100 dollars invested by stockholders. Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.04. The current year's Return On Capital Employed is expected to grow to 0.03. At present, Kamada's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 194.2 M, whereas Non Currrent Assets Other are forecasted to decline to about 550.3 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| William CPA | Organogenesis Holdings | N/A | |
| Mark CPA | Evoke Pharma | 47 | |
| Anil Namboodiripad | Dr Reddys Laboratories | 54 | |
| Charles Laranjeira | Pacira BioSciences, | 58 | |
| Christine CPA | Prestige Brand Holdings | 48 | |
| Lauren Riker | Pacira BioSciences, | 45 | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Christopher Young | Pacira BioSciences, | 52 | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| YUGANDHAR PUVVALA | Dr Reddys Laboratories | 48 | |
| Erin Gull | Cumberland Pharmaceuticals | N/A | |
| Kyle Hanson | Perrigo Company PLC | 59 | |
| Mary MD | ANI Pharmaceuticals | N/A | |
| Larry Miller | Phibro Animal Health | 60 | |
| Kumar Singh | Dr Reddys Laboratories | 74 | |
| Thomas Pearl | Organogenesis Holdings | N/A | |
| Deepak Sapra | Dr Reddys Laboratories | 45 | |
| Sushrut Kulkarni | Dr Reddys Laboratories | 54 | |
| Richa Periwal | Dr Reddys Laboratories | N/A | |
| Michael MD | Ironwood Pharmaceuticals | 65 | |
| Krishna MS | Dr Reddys Laboratories | 51 | |
Management Performance
| Return On Equity | 0.0705 | ||||
| Return On Asset | 0.0316 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Tsur, Co-Founder and Deputy Executive Chairman | ||
| LLB BA, General VP | ||
| Boris Gorelik, Vice Programs | ||
| Liron Reshef, Vice Resources | ||
| Chaime Orlev, Chief Officer | ||
| Yifat Esq, Gen Legal | ||
| Amir London, Chief Officer | ||
| Ariella Raban, VP HR | ||
| Eran Nir, Chief Officer | ||
| Hanni Neheman, Vice Sales | ||
| Shavit Beladev, Vice Plasma | ||
| Jon Knight, Vice Operations |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0705 | ||||
| Return On Asset | 0.0316 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 273 M | ||||
| Shares Outstanding | 57.49 M | ||||
| Shares Owned By Insiders | 7.31 % | ||||
| Shares Owned By Institutions | 50.10 % | ||||
| Number Of Shares Shorted | 29.33 K | ||||
| Price To Earning | 11.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kamada. If investors know Kamada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kamada listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1 | Earnings Share 0.27 | Revenue Per Share 2.837 | Quarterly Revenue Growth 0.134 | Return On Assets 0.0316 |
The market value of Kamada is measured differently than its book value, which is the value of Kamada that is recorded on the company's balance sheet. Investors also form their own opinion of Kamada's value that differs from its market value or its book value, called intrinsic value, which is Kamada's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kamada's market value can be influenced by many factors that don't directly affect Kamada's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kamada's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kamada is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kamada's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.